Publicacións (32) Publicacións de Juan Ruiz Bañobre

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

  2. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  3. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

    Journal of Experimental and Clinical Cancer Research, Vol. 43, Núm. 1

2023

  1. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  2. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

  3. Genetic and immune landscape evolution in MMR-deficient colorectal cancer

    Journal of Pathology

  4. Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time?

    JAMA Oncology

  5. MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles

    iScience, Vol. 26, Núm. 3

  6. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

    eClinicalMedicine, Vol. 58

  7. Noninvasive detection of microsatellite instability in patients with endometrial cancer

    International Journal of Cancer, Vol. 152, Núm. 10, pp. 2206-2217

2022

  1. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy

    Scientific Reports, Vol. 12, Núm. 1

  2. Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA

    Clinical Epigenetics, Vol. 14, Núm. 1

  3. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma

    Journal of Cutaneous Pathology, Vol. 49, Núm. 5, pp. 472-481

2021

  1. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

    Nature Communications, Vol. 12, Núm. 1

  2. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  3. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy

    Advances in Cancer Research (Academic Press Inc.), pp. 231-304

  4. Molecularly targeted therapy in metastatic CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 357-364

  5. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation

    Carcinogenesis, Vol. 41, Núm. 11, pp. 1498-1506

  2. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13